正畸复发研究领域中4种有前景的生物药物的研究进展  

Progress of the research on four promising biopharmaceuticals for intervening in orthodontic recurrence

作　　者：刘曼 孟耀[2] 牛茂 Liu Man;Meng Yao;Niu Mao(School of Medical Technology and Nursing,Shenzhen Polytechnic University,Shenzhen 518048,China;Dept.of Orthodontics,Shenzhen Children’s Hospital,Shenzhen 518000,China)

机构地区：[1]深圳职业技术大学医学技术与护理学院,深圳518048 [2]深圳市儿童医院口腔正畸科,深圳518000

出　　处：《国际口腔医学杂志》2024年第6期699-705,共7页International Journal of Stomatology

基　　金：广东省教育厅普通高校特色创新类项目(2019GKTSCX-091);深圳市科技创新委员会自由探索项目(JCYJ2018022816495-7104);深圳市科技创新委员会高校稳定支持项目([2021]0877)。

摘　　要：正畸术后复发是口腔正畸学研究热点之一。目前观点认为由于正畸牙移动和正畸牙复发期间发生的生理模式具有相似性,所以通过靶向参与牙槽骨改建的降低正畸牙移动速率的生物化学制剂可以潜在地调节正畸牙复发。通过局部给药和全身给药干预正畸复发的相关研究药物目前主要处于体外实验研究阶段。在动物实验中观察到一些生物药物具有其无创、不良反应小、干预方便等特点,成为近年来应用于干预正畸复发相关研究的重要方向。本文针对补骨脂、植物雌激素依普黄酮、乳铁蛋白、雌激素受体调节剂雷洛昔芬这4类生物药物的相关成骨机制及其在正畸术后复发领域的基础研究进行综述。Orthodontic relapse remains a prominent focus in orthodontic research owing to its clinical importance.Cur-rent insights suggest that the physiological similarity between orthodontic tooth movement and subsequent relapse war-rants the exploration of biochemical agents targeting alveolar bone remodeling processes.Such agents,which can modu-late the rate of orthodontic tooth movement,hold promise for regulating orthodontic relapse.The investigation of interven-tions for orthodontic relapse,primarily through local and systemic drug administration,is predominantly in the in vitro ex-perimental stage.Notably,in animal studies,certain biopharmaceuticals have emerged as pivotal avenues of research due to their noninvasive nature,minimal side effects,and facile administration.This review synthesizes the osteogenic mecha-nisms and foundational research concerning four classes of biological drugs implicated in postorthodontic relapse:pso-ralen,phytoestrogenic isoflavone,lactoferrin,and the estrogen receptor modulator raloxifene.

关 键 词：正畸牙移动 复发 生物医学药物 中成药 

分 类 号：R783.5[医药卫生—口腔医学]